Contributing writer · PharmD, PhD (Pharmacology)
A Pharm-D and PhD in Pharmacology from Punjab University College of Pharmacy, and I have worked as a registered hospital pharmacist at Jinnah Hospital Lahore. Over the past six years in clinical practice, I have seen…
A Pharm-D and PhD in Pharmacology from Punjab University College of Pharmacy, and I have worked as a registered hospital pharmacist at Jinnah Hospital Lahore. Over the past six years in clinical practice, I have seen how confusing medical information can be, even for professionals. That’s what pushed me toward writing. I have worked as a Member of Advisory Board for couple of Multinational Health firms. I specialize in turning dense research, clinical data, and regulatory details into content that’s clear, practical, and genuinely useful. Whether I am breaking down a study, reviewing a healthcare product, or writing patient friendly guidance, my goal is simple: accuracy first, clarity always. I believe good medical writing should inform, guide and build trust, not overwhelm the reader.
PharmD, PhD (Pharmacology)
Cardiology
The first consolidated US multisociety guideline for adults with acute pulmonary embolism introduces an A-to-E severity taxonomy and gives Pulmonary Embolism Response Teams a class 1 recommendation.
Dr. Abu Bakar · 7 min read
Infectious Disease
The FDA approved bepirovirsen for certain adults with chronic hepatitis B without cirrhosis. It is added to established antiviral therapy, not substituted for it.
Dr. Abu Bakar · 7 min read
Oncology
The verified FDA indication covers adults with HRR gene-mutated metastatic castration-resistant prostate cancer, making an approved companion diagnostic essential before talazoparib plus enzalutamide.
Dr. Abu Bakar · 6 min read
Cardiology
In a randomized trial, TAVR lowered the two-year risk of death or heart-failure hospitalization in patients with moderate aortic stenosis and at-risk features.
Dr. Abu Bakar · 6 min read
Innovation & Devices
The FDA has granted accelerated approval to plasmid DNA-based Voceryq for adults with HPV-associated recurrent respiratory papillomatosis, adding an option while confirmatory evidence is developed.
Dr. Abu Bakar · 6 min read
Cardiology
SIMPLAAFY compared reduced-dose oral anticoagulation or aspirin alone with dual antiplatelet therapy after left atrial appendage closure, finding similar stroke rates and less bleeding over 6 months.
Dr. Abu Bakar · 6 min read
Cardiology
An FDA early alert flags an Edwards transcatheter mitral-valve delivery system, but the available record does not name a model, event count or corrective action.
Dr. Abu Bakar · 6 min read
Endocrinology & Metabolism
The FDA boxed warning highlights serious hypophosphatemia with ferric carboxymaltose, particularly after repeated exposure. Treatment selection should now include phosphate risk, counseling and monitoring needs.
Dr. Abu Bakar · 7 min read
Infectious Disease
The Class I recall applies to specified Medline convenience kits containing recalled BD ChloraPrep applicators. Hospitals and other users should match both kit identifiers and lots against the FDA notice.
Dr. Abu Bakar · 6 min read
Oncology
The FDA approved talazoparib plus enzalutamide for adults with HRR-mutated metastatic prostate cancer that remains naïve or sensitive to androgen-pathway modulation. An FDA-authorized test must confirm eligibility.
Dr. Abu Bakar · 7 min read
Conference Coverage
Alpha and beta emitters bring distinct dosimetry, manufacturing and safety challenges. A conference review highlights why their development cannot be judged as a cross-cancer efficacy contest.
Dr. Abu Bakar · 7 min read
Oncology
The FDA approved lirafugratinib for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement, adding a biomarker-defined option after earlier therapy.
Dr. Abu Bakar · 6 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after endocrine progression. ESR1 testing now determines eligibility.
Dr. Abu Bakar · 6 min read
Innovation & Devices
Updated Amplatzer Amulet instructions sort pulmonary artery injury risk into three distance bands for patients undergoing left atrial appendage closure.
Dr. Abu Bakar · 6 min read
Oncology
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer, adding a bladder-preserving option for this underserved group.
Dr. Abu Bakar · 7 min read
Health Policy
An FDA Class I recall covers specified CooperSurgical INCA infant nasal CPAP set lots because tubing-to-cannula connections may loosen and interrupt respiratory support.
Dr. Abu Bakar · 6 min read
Infectious Disease
The Class I recall applies to Medline convenience kits containing affected BD ChloraPrep applicators. Facilities should quarantine listed inventory and assess patients with credible exposure and compatible illness.
Dr. Abu Bakar · 6 min read
Endocrinology & Metabolism
The FDA boxed warning makes hypophosphatemia a central consideration when ferric carboxymaltose is selected, particularly for patients with risk factors or repeated exposure.
Dr. Abu Bakar · 6 min read
Innovation & Devices
Par Health recalled two lots of premixed dexmedetomidine after cellulose or stopper material was found. Critical care and procedural teams should quarantine affected inventory before use.
Dr. Abu Bakar · 6 min read
Innovation & Devices
The Class I correction applies to affected AVID Medical convenience kits containing Huons sodium chloride ampules. Facilities should quarantine stock, trace prior use and assess possible exposures.
Dr. Abu Bakar · 6 min read
Infectious Disease
An FDA Class I recall covers IV-start and convenience kits containing skin-preparation products contaminated with Aspergillus penicillioides. Health systems need coordinated inventory tracing and exposure review.
Dr. Abu Bakar · 7 min read
Mental & Behavioral Health
Randomized evidence suggests psilocybin-assisted therapy can reduce depressive symptoms through six weeks, but safety, durability and implementation questions limit its immediate US clinical role.
Dr. Abu Bakar · 6 min read
Clinical Briefs
A nationwide recall covers compounded glutathione, Myers’ cocktail and Tri-Immune Boost injections. Infusion practices should quarantine affected stock and review patient exposure.
Dr. Abu Bakar · 7 min read
Cardiology
A randomized-trial review favors SGLT2 inhibitors for heart failure hospitalization, while mortality differences from GLP-1 receptor agonists remain less certain.
Dr. Abu Bakar · 6 min read
Clinical Briefs
Temporary FDA guidance creates a regulatory bridge for neonatal starter parenteral nutrition as the predominant market source prepares to exit. Hospital pharmacies still must meet the policy’s conditions and core quality obligations.
Dr. Abu Bakar · 7 min read
Clinical Briefs
The FDA expanded a Class I recall covering specific lots of reprocessed electrophysiology and ultrasound catheters because particulates may remain on patient-contacting surfaces.
Dr. Abu Bakar · 6 min read
Endocrinology & Metabolism
The FDA approved tiratricol as the first treatment for peripheral thyrotoxicosis in MCT8 deficiency, targeting cardiovascular and metabolic manifestations rather than the disorder’s established neurologic disability.
Dr. Abu Bakar · 6 min read
Health Policy
WHO’s access initiative shifts the pediatric sickle cell agenda toward delivery. Health systems must connect early diagnosis with preventive care, treatment, referral and long-term follow-up through age 19.
Dr. Abu Bakar · 6 min read
Infectious Disease
Baxter recalled one lot of cefazolin in dextrose injection after cardboard particulate matter was found. Pharmacies and perioperative teams should isolate affected inventory while maintaining prophylaxis workflows.
Dr. Abu Bakar · 6 min read
Endocrinology & Metabolism
ACHIEVE-5 reports better glycemic control and weight outcomes without more hypoglycemia when oral orforglipron is added to titrated insulin glargine, but the numerical results are essential to judge clinical value.
Dr. Abu Bakar · 6 min read